Literature DB >> 19917159

Serum levels of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) and pentraxin 3 (PTX3) as markers of infection in febrile patients with systemic lupus erythematosus.

J Kim1, J K Koh, E Y Lee, J A Park, H A Kim, E B Lee, C Garlanda, A Cotena, Y W Song.   

Abstract

OBJECTIVE: To investigate the role of sTREM-1 and PTX3 as markers of infection in febrile patients with SLE.
METHODS: In febrile (body temperature > or =38 degrees C) patients with SLE, blood samples of day 0, 1, 2, and 14 after presentation were drawn and relevant clinical data were collected. The patients were allocated to an infection group (n=19) or disease flare group (n=14). Serum levels of sTREM-1 and PTX3 were measured by ELISA using the serum samples of SLE patients and age- and sex-matched healthy controls (n=31).
RESULTS: A total of 33 febrile episodes occurred in 32 SLE patients (19 infections, 14 flares) were studied. sTREM-1 levels on day 0 were significantly higher in the infection group than in the flare group (109.9 pg/ml (median) vs. 48.0 pg/ml, p=0.002), but PTX3 levels were similar in these two groups. The difference of sTREM-1 levels between infection group and flare group was persistent on day 1 and 2 (day 1, p=0.007; day 2, p=0.034). The highest diagnostic value (sensitivity=1.0, specificity=0.664) of sTREM-1 was obtained at the threshold value of 53.2 pg/mL.
CONCLUSION: Serum sTREM-1 levels were significantly higher in the infection group than in the flare group of febrile SLE patients. Our findings suggest that serum sTREM-1 levels could be used to determine whether SLE patients have contracted an infection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19917159

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  7 in total

1.  Pentraxin 3 increase is much less pronounced than C-reactive protein increase after surgical procedures.

Authors:  Torbjörn Åkerfeldt; Anders Larsson
Journal:  Inflammation       Date:  2011-10       Impact factor: 4.092

2.  Comparison of soluble urokinase plasminogen activator receptor, soluble triggering receptor expressed on myeloid cells 1, procalcitonin and C-reactive protein in distinguishing concurrent bacterial infection from idiopathic inflammatory myopathy.

Authors:  Yizhi Xiao; Hui Luo; Bin Zhou; Xiaodan Dai; Jing Huang; Liping Duan; Yunhui You; Weiru Zhang; Hongjun Zhao; Yanli Xie; Yaou Zhou; Wangbin Ning; Tong Li; Sijia Liu; Honglin Zhu; Xiaoyun Xie; Ying Jiang; Shiyao Wu; Weijia He; Yisha Li
Journal:  Rheumatol Int       Date:  2016-11-22       Impact factor: 2.631

3.  Serum soluble triggering receptor on myeloid cells-1 (sTREM-1) is elevated in systemic lupus erythematosus but does not distinguish between lupus alone and concurrent infection.

Authors:  Yair Molad; Elisheva Pokroy-Shapira; Tania Kaptzan; Assaf Monselise; Michal Shalita-Chesner; Yehudit Monselise
Journal:  Inflammation       Date:  2013-12       Impact factor: 4.092

4.  Lifestyle intervention is associated with decreased concentrations of circulating pentraxin 3 independent of CRP decrease.

Authors:  Anders Larsson; Göran Ronquist; Torbjörn Åkerfeldt
Journal:  Ups J Med Sci       Date:  2013-08       Impact factor: 2.384

Review 5.  Protective molecules and their cognate antibodies: new players in autoimmunity.

Authors:  Margherita Zen; Nicola Bassi; Carla Campana; Silvano Bettio; Elena Tarricone; Linda Nalotto; Anna Ghirardello; Andrea Doria
Journal:  Auto Immun Highlights       Date:  2010-11-04

6.  Blood monocyte chemotactic protein-1 (MCP-1) and adapted disease activity Score28-MCP-1: favorable indicators for rheumatoid arthritis activity.

Authors:  Lieh-bang Liou; Wen-pin Tsai; Chee J Chang; Wan-ju Chao; Meng-hsin Chen
Journal:  PLoS One       Date:  2013-01-30       Impact factor: 3.240

7.  Prospective Evaluation of Procalcitonin, Soluble Triggering Receptor Expressed on Myeloid Cells-1 and C-Reactive Protein in Febrile Patients with Autoimmune Diseases.

Authors:  Chou-Han Lin; Song-Chou Hsieh; Li-Ta Keng; Ho-Sheng Lee; Hou-Tai Chang; Wei-Yu Liao; Chao-Chi Ho; Chong-Jen Yu
Journal:  PLoS One       Date:  2016-04-20       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.